Le Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Le Tang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Jiarui Yao
Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
83 shared publications - Yuankai Shi
Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
72 shared publications - Xiaohong Han
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
70 shared publications - Juan Cai
Department of Blood Transfusion, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021
62 shared publications - Rongrong Luo
Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
62 shared publications - Xiying Li
Department of Blood Transfusion, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021
62 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Univariate association analysis for progression-free survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Univariate association analysis for progression-free survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Treatment in representative patient
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Treatment in representative patient
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Confirmed best overall response per RECIST v1.1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Confirmed best overall response per RECIST v1.1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Univariate association analysis for overall survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Univariate association analysis for overall survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Next-Generation Sequencing results
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Next-Generation Sequencing results
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Flow diagram of patient disposition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study
Flow diagram of patient disposition
- Open Access
- 29 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3966-3982
Digital spatial profiling uncovers transcriptomic features of distinct plasma cell–like phenotypes in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) exhibits marked heterogeneity, complicating treatment and prognosis. The role of plasma cell–like phenotypes in DLBCL remains underexplored. Using spatially resolved transcriptomics, we profiled 4 distinct plasma cell–like phenotypes in DLBCL based on CD20, HLA-DRA, and PR domain zinc finger protein 1 (PRDM1) markers: CD20+HLA-DRA+ PRDM1−, CD20+ HLA-DRA+ PRDM1+, CD20+ HLA-DRA−PRDM1−, and CD20+ HLA-DRA−PRDM1+. The CD20+ HLA-DRA+ PRDM1− phenotype (nonplasma cell–like phenotype) had better prognosis; the other 3 phenotypes (plasma cell–like phenotypes) had worse prognosis. Patients with >30% plasma cell–like phenotype cells were classified as DLBCL plasma cell–like phenotype predominant (DLBCLPCPP), and those with ≤30% as DLBCL plasma cell–like phenotype deficient (DLBCLPCPD). Plasma cell–like phenotype cells correlated with reduced proliferation, impaired immune function, and enhanced tumor microenvironment remodeling. DLBCLPCPP had lower Ki-67 index of ≥85% (29.6% vs 53.9%, P = .0198), similar first-line response (92.6% vs 92.6%, P = 1.00) but a higher rate of disease progression within 12 months (25.9% vs 3.7%, P = .0238) and more B2M alterations (22.2% vs 3.7%, P = .0509) compared with DLBCLPCPD. Transcriptomic revealed of plasma cell–like phenotype cells to plasmablastic lymphoma. Using phenotype-associated genes, we constructed a random forest model to predict bortezomib response. High plasma cell–like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) plus bortezomib (RB-CHOP), low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell–like phenotypes in DLBCL, offering new insights for prognostic relevance and individualized treatment strategies.
- 29 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (11) , 3966-3982
Open AccessDigital spatial profiling uncovers transcriptomic features of distinct plasma cell–like phenotypes in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) exhibits marked heterogeneity, complicating treatment and prognosis. The role of plasma cell–like phenotypes in DLBCL remains underexplored. Using spatially resolved transcriptomics, we profiled 4 distinct plasma cell–like phenotypes in DLBCL based on CD20, HLA-DRA, and PR domain zinc finger protein 1 (PRDM1) markers: CD20+HLA-DRA+ PRDM1−, CD20+ HLA-DRA+ PRDM1+, CD20+ HLA-DRA−PRDM1−, and CD20+ HLA-DRA−PRDM1+. The CD20+ HLA-DRA+ PRDM1− phenotype (nonplasma cell–like phenotype) had better prognosis; the other 3 phenotypes (plasma cell–like phenotypes) had worse prognosis. Patients with >30% plasma cell–like phenotype cells were classified as DLBCL plasma cell–like phenotype predominant (DLBCLPCPP), and those with ≤30% as DLBCL plasma cell–like phenotype deficient (DLBCLPCPD). Plasma cell–like phenotype cells correlated with reduced proliferation, impaired immune function, and enhanced tumor microenvironment remodeling. DLBCLPCPP had lower Ki-67 index of ≥85% (29.6% vs 53.9%, P = .0198), similar first-line response (92.6% vs 92.6%, P = 1.00) but a higher rate of disease progression within 12 months (25.9% vs 3.7%, P = .0238) and more B2M alterations (22.2% vs 3.7%, P = .0509) compared with DLBCLPCPD. Transcriptomic revealed of plasma cell–like phenotype cells to plasmablastic lymphoma. Using phenotype-associated genes, we constructed a random forest model to predict bortezomib response. High plasma cell–like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) plus bortezomib (RB-CHOP), low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell–like phenotypes in DLBCL, offering new insights for prognostic relevance and individualized treatment strategies.
- Open Access
- 1 February 2026
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 4 (1) , 126-138
Diabetes-associated metabolic-immune signature stratifies survival and immunotherapy response in pancreatic adenocarcinoma through multi-omics integration
- 1 February 2026
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 4 (1) , 126-138
Open AccessDiabetes-associated metabolic-immune signature stratifies survival and immunotherapy response in pancreatic adenocarcinoma through multi-omics integration
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.